The following listing of claims is to replace all prior versions of the claims:

Listing of the Claims:

Claim 1 (currently amended): An oligonucleotide 8 to 30 nucleotides in length which is targeted to a nucleic acid encoding human Ki-ras, wherein said oligonucleotide is capable of inhibiting Ki-ras expression, and wherein said oligonucleotide comprises at least an 8-nucleobase portion of SEQ ID NO: 20, 21, 22, ~~26, 28,~~ 31, 32 or 33.

Claims 2-6 (canceled).

Claim 7 (original): The oligonucleotide of claim 1 which comprises at least one backbone modification.

Claim 8 (original): The oligonucleotide of claim 1 wherein at least one of the nucleotide units of said oligonucleotide is modified at the 2' position of the sugar,

Claim 9 (original): The oligonucleotide of claim 1 which is a chimeric oligonucleotide.

Claim 10 (original): The oligonucleotide of claim 1 in a pharmaceutically acceptable carrier.

Claim 11 (currently amended): A method of modulating the expression of human Ki-ras comprising contacting tissues or cells containing a human Ki-ras gene with an effective amount of an oligonucleotide ~~of claim 1~~ 8 to 30 nucleotides in length which is targeted to a nucleic acid encoding human Ki-ras, wherein said oligonucleotide is capable of inhibiting Ki-ras expression, wherein said oligonucleotide comprises at least an 8-nucleobase portion of SEQ ID NO: 20, 21, 22, 26, 28, 31, 32 or 33 and whereby expression of Ki-ras is modulated.

Claim 12 (currently amended): A method of inhibiting the proliferation of cancer cells comprising contacting cancer cells with an effective amount of an oligonucleotide ~~of claim 1~~ 8 to 30 nucleotides in length which is targeted to a nucleic acid encoding human Ki-ras, wherein said oligonucleotide is capable of inhibiting Ki-ras expression, wherein said oligonucleotide comprises at least an 8-nucleobase portion of SEQ ID NO: 20, 21, 22, 26, 28, 31, 32 or 33 and, whereby proliferation of the cancer cells is inhibited.

Claim 13 (currently amended): A method of preventing or treating a condition arising from the activation of a Ki-ras oncogene comprising contacting an animal suspected of having a condition arising from the activation of a Ki-ras oncogene with an

effective amount of an oligonucleotide ~~of claim 1~~ 8 to 30 nucleotides in length which is targeted to a nucleic acid encoding human Ki-ras, wherein said oligonucleotide is capable of inhibiting Ki-ras expression, wherein said oligonucleotide comprises at least an 8-nucleobase portion of SEQ ID NO: 20, 21, 22, 26, 28, 31, 32 or 33 and, whereby said condition is prevented or treated.

Claim 14 (previously presented): The method of claim 13 wherein said activation of a Ki-ras oncogene is abnormal expression of a Ki-ras oncogene.

Claim 15 (original): The method of claim 13 wherein said condition is a hyperproliferative condition.

Claim 16 (original): The method of claim 13 wherein the condition is cancer.

Claim 17 (original): The method of claim 13 wherein the condition is colorectal cancer, melanoma, liposarcoma, mesothelioma, sarcoma, colon cancer, or pancreatic cancer.

Claim 18 (original): The method of claim 11 wherein the cells are cancer cells.

Claim 19 (original): The method of claim 11 wherein the cells are blood cells.

Claim 20 (original): The method of claim 11 wherein the cells are peripheral blood mononuclear cells.

Claims 21-23 (canceled).